pneumococcal pneumonia
Oct 06, 2026
Vaxcyte Announces Positive Phase 3 Topline Data for VAX-31 from OPUS-1 Trial; CSL and Alentis Partner to Advance Lixudebart for Rare Renal and Hepatic Diseases; Pfizer Announces Positive Repigmentation Results for LITFULO in Nonsegmental Vitiligo; AstraZeneca Completes Equity Investment in Summit Therapeutics; Lilly’s Jaypirca Receives FDA Approval Expansion for Certain Patients with Untreated CLL/SLL; Merck’s Tulisokibart Delivers Positive Phase 2b Results in Moderate-to-Severe Hidradenitis Suppurativa
Vaxcyte Reports Successful Topline Outcomes from Pivotal Phase 3 OPUS-1 Study of VAX-31 Vaxcyte, Inc. reported positive topline findings from OPUS-1, its pivotal Phase 3 trial in adults evaluating the safety, tolerability, and immunogenicity of VAX-31, the company’s next-generation 31-valent pneumococcal conjuga...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
